Plant Comparison
Astragalus vs Purple coneflower
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Astragalus and Purple coneflower: they share 6 indicated uses (arthritis / joint pain, cold & flu, immune support, …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Astragalus | Purple coneflower | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Cold & flu | 2/10 | 1/10 | Comparable evidence |
| Immune support | 2/10 | 1/10 | Comparable evidence |
| Infection (general) | 2/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Major bioactive saponin with cardio-, neuro-, hepato- and renoprotective effects.
Lipophilic alkamides are considered key immunomodulatory and anti-inflammatory constituents, particularly concentrated in the root.
Antioxidant phenolic compounds contributing to the plant's immunomodulatory activity.
Water-soluble polysaccharides associated with immune-stimulating activity, particularly from the aerial parts.
Pharmacological Actions
Astragalus membranaceus and its constituents (astragaloside IV, cycloastragenol, Astragalus polysaccharide) inhibit tumour growth, invasion and metastasis and enhance antitumour immunity across lung, colorectal and gastrointestinal cancers (preclinical, incl. in vivo).
Immune support / immunomodulation (activates macrophages, NK cells, T and B lymphocytes)
Traditional & Indicated Uses
inferred from anti-inflammatory action
Astragalus membranaceus protects against gastrointestinal cancers; astragaloside IV inhibits lung cancer metastasis via macrophage repolarization, cycloastragenol boosts CD8+ T-cell antitumour immunity (with anti-PD-1 synergy), and Astragalus polysaccharide suppresses inflammation-induced colorectal cancer (preclinical).
Supports resistance to colds and respiratory infection (immune)
Adaptogenic tonic for fatigue and low vitality (traditional 'Qi' tonic)
Immune support / immunomodulation (activates macrophages, NK cells, T and B lymphocytes); Supports resistance to colds and respiratory infection (immune)
Supports resistance to colds and respiratory infection (immune)
inferred from anti-inflammatory action
Renoprotective (kidney support) - as an adjunct in chronic kidney disease, reduced proteinuria and raised haemoglobin and serum albumin across trials (Cochrane review; study quality low)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from immunomodulator action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Safety, Cautions & Contraindications
Astragalus stimulates immune activity; on theoretical grounds it should be used cautiously in autoimmune disease and with immunosuppressant medicines (for example after organ transplant) - discuss with a clinician.
Generally well tolerated; high-quality long-term human safety and toxicity data remain limited.
Safety in pregnancy and breastfeeding has not been established; avoid medicinal doses.
Generally considered safe, but caution advised for those with autoimmune conditions. Not recommended for long-term use (more than 8 weeks continuously).
Duke (2002) rates echinacea as +++ — among the most thoroughly documented herbal immunostimulants. It notes experimental and clinical evidence for immunostimulant, antiviral, and anti-inflammatory activities. Multiple species have been studied (E. purpurea, E. angustifolia, E. pallida), and Duke emphasizes that species identification in commercial products is often unreliable. Commission E approves E. purpurea for supporting immune function during colds and flu. Dose: 900 mg standardized extract daily in acute use; use should be limited to 8 weeks continuous. Contraindicated in autoimmune diseases (MS, lupus, HIV/AIDS), tuberculosis, and with immunosuppressive drugs (cyclosporine) (Duke, 2002).
External Ids
Botanical Description
Erect perennial herb with a long, fibrous, pale yellow taproot. The leaves are pinnately compound with numerous small, oval leaflets, giving a soft, ferny appearance. Small, pale yellow, pea-like flowers are borne in loose axillary clusters (racemes), followed by membranous, inflated seed pods that give the species its name.[5]
Robust perennial herb with a basal rosette of coarse, hairy, lance-shaped leaves and tall, sturdy flowering stems. Each stem bears a single large, daisy-like flower head with drooping (reflexed), rose-purple to pink ray florets surrounding a prominent, spiny, orange-brown central cone of disc florets.[4]
Habitat
Native to the grasslands, sunny slopes and forest margins of northern and north-eastern China, Mongolia and parts of Korea; widely cultivated as a medicinal crop across East Asia.[5]
Native to the tallgrass prairies, open woodland and dry meadows of central and eastern North America; widely cultivated worldwide as a garden and medicinal plant.[4]
Harvesting
The root is dug from plants at least four years old, typically in spring or autumn, then cleaned and dried, often sliced into the characteristic pale, fibrous 'coin' slices used in traditional decoctions.[5]
The flower heads are picked as they open, in summer; the root is dug in autumn from plants at least two to three years old, when its content of bioactive alkamides and caffeic acid derivatives is highest, then cleaned and dried.[4]
Traditional Uses
Echinacea root was widely used by Native American peoples as a remedy for infections, wounds, snakebite and toothache, and entered nineteenth-century Eclectic medicine as a broad anti-infective. It remains best known today, in standardised aerial-part or root extracts, as a supportive remedy for preventing and shortening the common cold and supporting immune function.[1, 4]
Preparations
Fresh-pressed juice or standardised extract of the aerial parts or root, taken as tablets, drops or capsules at the first sign of a cold; the best-studied clinical form.
Dosage
The WHO monograph on Radix Astragali gives doses of 3-9 g per day. Traditional Chinese medicine references often cite a considerably higher 9-30 g of dried root per day; WHO's figure is the conservative regulatory-tier one and is stated here in preference. Educational reference only, not a prescription.
Clinical studies commonly use extracts providing the equivalent of several grams of dried root daily, in divided doses. Educational reference only, not a prescription.
Clinical trials for the common cold commonly use around 300-900 mg of standardised extract daily, started at the first sign of symptoms and continued for up to 7-10 days; continuous use beyond about 8 weeks is not recommended. Educational reference only, not a prescription.
References
Lookalikes Review
Drug Class Interactions
Not documented
References & Sources
- Xu, B., Huang, J.P., Peng, G., Cao, W., Liu, Z. et al (2024) 'Total biosynthesis of the medicinal triterpenoid saponin astragalosides', Nature Plants, 10(11), pp. 1826-1837. doi:10.1038/s41477-024-01827-4 Preclinical
https://doi.org/10.1038/s41477-024-01827-4 - Auyeung, K.K., Han, Q.B. and Ko, J.K (2016) 'Astragalus membranaceus: A Review of its Protection Against Inflammation and Gastrointestinal Cancers', The American Journal of Chinese Medicine, 44(1), pp. 1-22. doi:10.1142/S0192415X16500014 Traditional / reference
https://doi.org/10.1142/S0192415X16500014 - Zhang, Y., Ji, W., Qin, H., Chen, Z., Zhou, Y. et al (2024) 'Astragalus polysaccharides alleviate DSS-induced ulcerative colitis in mice by restoring SCFA production and regulating Th17/Treg cell homeostasis in a microbiota-dependent manner', Carbohydrate Polymers, 349, pp. 122829. doi:10.1016/j.carbpol.2024.122829 Preclinical
https://doi.org/10.1016/j.carbpol.2024.122829 - Fu, J., Wang, Z., Huang, L., Zheng, S., Wang, D., Chen, S., Zhang, H. and Yang, S (2014) 'Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi)', Phytotherapy Research, 28(9), pp. 1275-1283. doi:10.1002/ptr.5188 Meta-analysis / review
https://doi.org/10.1002/ptr.5188 - Zhang, J., Wu, C., Gao, L., Du, G. and Qin, X (2019) 'Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects', Advances in Pharmacology. doi:10.1016/bs.apha.2019.08.002 Traditional / reference
https://doi.org/10.1016/bs.apha.2019.08.002 - Dong, M., Li, J., Yang, D., Li, M. and Wei, J (2023) 'Biosynthesis and pharmacological activities of flavonoids, triterpene saponins and polysaccharides derived from Astragalus membranaceus', Molecules, 28(13), pp. 5018. doi:10.3390/molecules28135018 Meta-analysis / review
https://doi.org/10.3390/molecules28135018 - Chen, G., Jiang, N., Zheng, J., Hu, H., Yang, H., Lin, A., Hu, B. and Liu, H (2023) 'Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus', International Journal of Biological Macromolecules, 241, pp. 124386. doi:10.1016/j.ijbiomac.2023.124386 Preclinical
https://doi.org/10.1016/j.ijbiomac.2023.124386 - Zheng, Q., Zhuang, Z., Wang, Z., Deng, L., Jin, W., Huang, Z., Zheng, G. and Wang, Y (2020) 'Clinical and preclinical systematic review of Astragalus membranaceus for viral myocarditis', Oxidative Medicine and Cellular Longevity, 2020, pp. 1560353. doi:10.1155/2020/1560353 Meta-analysis / review
https://doi.org/10.1155/2020/1560353 - Dai, Y., Wang, Y., Kang, Q., Wu, Y., Liu, Y., Su, Y., Wang, X., Xiu, M. and He, J (2024) 'The protective effect and bioactive compounds of Astragalus membranaceus against neurodegenerative disorders via alleviating oxidative stress in Drosophila', FASEB Journal, 38(13), pp. e23727. doi:10.1096/fj.202400390R Preclinical
https://doi.org/10.1096/fj.202400390R - Xu, L., Xu, X., Hou, X., Wang, F., Gao, S. and Zhang, H (2019) 'Adjuvant therapy with Astragalus membranaceus for post-stroke fatigue: a systematic review', Metabolic Brain Disease, 35(1), pp. 83-93. doi:10.1007/s11011-019-00483-4 Meta-analysis / review
https://doi.org/10.1007/s11011-019-00483-4 - Li, C.X., Liu, Y., Zhang, Y.Z., Li, J.C. and Lai, J (2022) 'Astragalus polysaccharide: a review of its immunomodulatory effect', Archives of Pharmacal Research. doi:10.1007/s12272-022-01393-3 Preclinical
https://doi.org/10.1007/s12272-022-01393-3 - Jin, M., Zhao, K., Huang, Q. and Shang, P (2014) 'Structural features and biological activities of the polysaccharides from Astragalus membranaceus', International Journal of Biological Macromolecules, 64, pp. 257-266. doi:10.1016/j.ijbiomac.2013.12.002 Preclinical
https://doi.org/10.1016/j.ijbiomac.2013.12.002 - Liu, Y. and Lv, W (2019) 'Research progress in Astragalus membranaceus and its active components on immune responses in liver fibrosis', Chinese Journal of Integrative Medicine, 26(10), pp. 794-800. doi:10.1007/s11655-019-3039-1 Meta-analysis / review
https://doi.org/10.1007/s11655-019-3039-1 - World Health Organization (1999) 'Radix Astragali'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Xu, F. and Cui, W.-Q. and Wei, Y. and Cui, J. and Qiu, J. and Hu, L.-L. and Gong, W.-Y. and Dong, J.-C. and Liu, B.-J (2018) 'Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling', Journal of Experimental & Clinical Cancer Research, 37(1), pp. 207. doi:10.1186/s13046-018-0878-0 Preclinical
https://doi.org/10.1186/s13046-018-0878-0 - Deng, G. and Zhou, L. and Wang, B. and Sun, X. and Zhang, Q. and Chen, H. and Wan, N. and Ye, H. and Wu, X. and Sun, D. and Sun, Y. and Cheng, H (2022) 'Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation', Journal for ImmunoTherapy of Cancer, 10(10), pp. e004874. doi:10.1136/jitc-2022-004874 Preclinical
https://doi.org/10.1136/jitc-2022-004874 - Li, Q. and Zhang, C. and Xu, G. and Shang, X. and Nan, X. and Li, Y. and Liu, J. and Hong, Y. and Wang, Q. and Peng, G (2024) 'Astragalus polysaccharide ameliorates CD8 T cell dysfunction through STAT3/Gal-3/LAG3 pathway in inflammation-induced colorectal cancer', Biomedicine & Pharmacotherapy, 171, pp. 116172. doi:10.1016/j.biopha.2024.116172 Preclinical
https://doi.org/10.1016/j.biopha.2024.116172 - Zhang, H.W., Lin, Z.X., Xu, C., Leung, C. and Chan, L.S (2014) 'Astragalus (a traditional Chinese medicine) for treating chronic kidney disease', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD008369.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD008369.pub2
- Karsch-Völk, M., Barrett, B., Kiefer, D., Bauer, R. et al (2014) 'Echinacea for preventing and treating the common cold', Cochrane Database of Systematic Reviews, 2(2), pp. CD000530. doi:10.1002/14651858.CD000530.pub3 Meta-analysis / review
https://doi.org/10.1002/14651858.CD000530.pub3 - Kamin, W., Seifert, G., Zwiauer, K., Bonhoeffer, J. et al (2025) 'Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review', Frontiers in Pediatrics, 13, pp. 1423250. doi:10.3389/fped.2025.1423250 Meta-analysis / review
https://doi.org/10.3389/fped.2025.1423250 - Fashner, J., Ericson, K. and Werner, S (2012) 'Treatment of the common cold in children and adults', American Family Physician, 86(2), pp. 153-159. Available at: https://pubmed.ncbi.nlm.nih.gov/22962927/ Traditional / reference
https://pubmed.ncbi.nlm.nih.gov/22962927/ - Manayi, A., Vazirian, M. and Saeidnia, S (2015) 'Echinacea purpurea: Pharmacology, phytochemistry and analysis methods', Pharmacognosy Reviews, 9(17), pp. 63-72. doi:10.4103/0973-7847.156353 Meta-analysis / review
https://doi.org/10.4103/0973-7847.156353 - Burlou-Nagy, C., Banica, F., Jurca, T., Vicas, L.G., Marian, E., Muresan, M.E., Bacskay, I., Kiss, R., Feher, P. and Pallag, A (2022) 'Echinacea purpurea (L.) Moench: Biological and Pharmacological Properties. A Review', Plants, 11(9), pp. 1244. doi:10.3390/plants11091244 Meta-analysis / review
https://doi.org/10.3390/plants11091244 - Hall, H., Fahlman, M.M. and Engels, H.J (2007) 'Echinacea purpurea and mucosal immunity', International Journal of Sports Medicine, 28(9), pp. 792-797. doi:10.1055/s-2007-964895 Randomized trial
https://doi.org/10.1055/s-2007-964895 - Ross, S.M (2016) 'Echinacea purpurea: A Proprietary Extract of Echinacea purpurea Is Shown to be Safe and Effective in the Prevention of the Common Cold', Holistic Nursing Practice, 30(1), pp. 54-57. doi:10.1097/HNP.0000000000000130 Meta-analysis / review
https://doi.org/10.1097/HNP.0000000000000130 - Hudson, J.B (2011) 'Applications of the phytomedicine Echinacea purpurea (Purple Coneflower) in infectious diseases', Journal of Biomedicine & Biotechnology, 2012, pp. 769896. doi:10.1155/2012/769896 Meta-analysis / review
https://doi.org/10.1155/2012/769896 - Mishima, S., Saito, K., Maruyama, H., Inoue, M., Yamashita, T., Ishida, T. and Gu, Y (2004) 'Antioxidant and immuno-enhancing effects of Echinacea purpurea', Biological & Pharmaceutical Bulletin, 27(7), pp. 1004-1009. doi:10.1248/bpb.27.1004 Preclinical
https://doi.org/10.1248/bpb.27.1004 - Saunders, P.R., Smith, F. and Schusky, R.W (2007) 'Echinacea purpurea L. in children: safety, tolerability, compliance, and clinical effectiveness in upper respiratory tract infections', Canadian Journal of Physiology and Pharmacology, 85(11), pp. 1195-1199. doi:10.1139/Y07-103 Clinical study
https://doi.org/10.1139/Y07-103 - Micheli, L., Maggini, V., Ciampi, C., Gallo, E., Bogani, P., Fani, R., Pistelli, L., Ghelardini, C., Di Cesare Mannelli, L., De Leo, M. and Firenzuoli, F (2022) 'Echinacea purpurea against neuropathic pain: Alkamides versus polyphenols efficacy', Phytotherapy Research, 37(5), pp. 1911-1923. doi:10.1002/ptr.7709 Preclinical
https://doi.org/10.1002/ptr.7709 - Gholami, M., Amri, J., Pazhoohan, S. and Sadegh, M (2021) 'Anticonvulsive and anti-epileptogenesis effects of Echinacea purpurea root extract, an involvement of CB2 receptor', Journal of Complementary & Integrative Medicine, 19(4), pp. 879-886. doi:10.1515/jcim-2020-0219 Preclinical
https://doi.org/10.1515/jcim-2020-0219 - Awortwe, C., Bruckmueller, H., Kaehler, M. and Cascorbi, I (2021) 'Interaction of Phytocompounds of Echinacea purpurea with ABCB1 and ABCG2 Efflux Transporters', Molecular Pharmaceutics, 18(4), pp. 1622-1633. doi:10.1021/acs.molpharmaceut.0c01075 Preclinical
https://doi.org/10.1021/acs.molpharmaceut.0c01075 - Perry, N.B., van Klink, J.W., Burgess, E.J. and Parmenter, G.A (1997) 'Alkamide levels in Echinacea purpurea: a rapid analytical method revealing differences among roots, rhizomes, stems, leaves and flowers', Planta Medica, 63(1), pp. 58-62. doi:10.1055/s-2006-957605 Preclinical
https://doi.org/10.1055/s-2006-957605 - Linde, K., Barrett, B., Wölkart, K., Bauer, R. and Melchart, D (2006) 'Echinacea for preventing and treating the common cold'. Traditional / reference
https://scholar.google.com/scholar?q=Echinacea%20for%20preventing%20and%20treating%20the%20common%20cold - Sharma, M., Schoop, R., Suter, A. and Schoop, W (2010) 'The possibility of prophylactic treatment of streptococcal pharyngotonsillitis with a standardized Echinacea preparation', 29(8), pp. 1025--1035. Traditional / reference
https://scholar.google.com/scholar?q=The%20possibility%20of%20prophylactic%20treatment%20of%20streptococcal%20pharyngotonsillitis%20with%20a%20standardized%20Echinacea%20preparation - World Health Organization (1999) 'WHO Monographs on Selected Medicinal Plants'. Traditional / reference
https://scholar.google.com/scholar?q=WHO%20Monographs%20on%20Selected%20Medicinal%20Plants - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Gorski, J.C., Huang, S.M., Pinto, A., Hamman, M.A., Hilligoss, J.K., Zaheer, N.A., Desai, M., Miller, M. and Hall, S.D (2004) 'The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo', Clinical Pharmacology and Therapeutics, 75(1), pp. 89-100. doi:10.1016/j.clpt.2003.09.013 Clinical study
https://doi.org/10.1016/j.clpt.2003.09.013
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.